Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion
NNovartis

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion

  • 2026-05-19

Novartis NOVN -1.20%decrease; red down pointing triangle said it agreed to buy biotech company Excellergy for up to $2 billion, adding a new approach to treat allergic diseases to its immunology pipeline.

The Swiss pharmaceutical company said Friday that the deal for privately held Excellergy brings in a drug candidate in early-stage trials with potential to complement its existing allergy portfolio.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

  • Tags:
  • acquisitions
  • Acquisitions/Mergers
  • Acquisitions/Mergers/Shareholdings
  • Allergies
  • allergy treatments
  • C&E Industry News Filter
  • cancer drugs
  • CH:NOVN
  • Content Types
  • corporate
  • Corporate Actions
  • Corporate/Industrial News
  • development
  • Factiva Filters
  • GCAPI
  • General news
  • Health
  • Healthcare
  • Healthcare/Life Sciences
  • industrial news
  • Industrial Property Rights
  • Intellectual Property Rights
  • life sciences
  • LINK:EN|drn:realtime.linkedarticle.DNCO20260327002828
  • Manufacturing
  • Medical Conditions
  • mergers
  • new product
  • New Product/Service Testing
  • new products
  • New Products/Services
  • newsplus
  • Novartis
  • NOVN.EB
  • Ownership Changes
  • Patents
  • Pharmaceuticals
  • political
  • Political/General News
  • products
  • Products/Services
  • research
  • Research/Development
  • Respiratory
  • Respiratory/Allergy Treatments
  • service testing
  • Services
  • shareholdings
  • SYND
  • WSJ-PRO-WSJ.com
Switzerland
www.europesays.com